Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke
NCT ID: NCT00147602
Last Updated: 2015-04-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
4732 participants
INTERVENTIONAL
1998-11-30
2005-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Atorvastatin in Acute Stroke Treatment
NCT02225834
Atorvastatin for Preventing Occlusion and Restenosis After Intracranial Artery Stenting
NCT01255852
Effect of Short Term Atorvastatin Treatment,80mg/Day on Early Regression of Carotid Artery Atherosclerotic Lesions
NCT00640744
Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation
NCT06308952
High-Dose Atorvastatin for Vascular Wall Protection in Thrombectomy Patients
NCT05912686
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
atorvastatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
East Gosford, New South Wales, Australia
Pfizer Investigational Site
Randwick, Sydney, New South Wales, Australia
Pfizer Investigational Site
Footscray, Victoria, Australia
Pfizer Investigational Site
Heidelberg Heights, Victoria, Australia
Pfizer Investigational Site
Parkville, Victoria, Australia
Pfizer Investigational Site
Prahran, Victoria, Australia
Pfizer Investigational Site
Perth, Western Australia, Australia
Pfizer Investigational Site
Graz, , Austria
Pfizer Investigational Site
Innsbruck, , Austria
Pfizer Investigational Site
Vienna, , Austria
Pfizer Investigational Site
Villach, , Austria
Pfizer Investigational Site
Ghent, , Belgium
Pfizer Investigational Site
Leuven, , Belgium
Pfizer Investigational Site
Tielt, , Belgium
Pfizer Investigational Site
Waregem, , Belgium
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
Viña del Mar, , Chile
Pfizer Investigational Site
Brno, , Czechia
Pfizer Investigational Site
Ostrava, , Czechia
Pfizer Investigational Site
Ostrava-Poruba, , Czechia
Pfizer Investigational Site
Pilsen, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Zlín, , Czechia
Pfizer Investigational Site
Copenhagen Nv, , Denmark
Pfizer Investigational Site
Glostrup Municipality, , Denmark
Pfizer Investigational Site
Hellerup, , Denmark
Pfizer Investigational Site
Hus, Helsinki, , Finland
Pfizer Investigational Site
Kotka, , Finland
Pfizer Investigational Site
Kuopio, , Finland
Pfizer Investigational Site
Lahti, , Finland
Pfizer Investigational Site
Lappeenranta, , Finland
Pfizer Investigational Site
Oulu, , Finland
Pfizer Investigational Site
Saint-Denis, Cedex 1, France
Pfizer Investigational Site
Paris, Cedex 20, France
Pfizer Investigational Site
Toulouse, Cedex 3, France
Pfizer Investigational Site
Bourg-en-Bresse, Cedex, France
Pfizer Investigational Site
Besançon, , France
Pfizer Investigational Site
Marseille, , France
Pfizer Investigational Site
Nice, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Bad Rodach, , Germany
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Essen, , Germany
Pfizer Investigational Site
Heidelberg, , Germany
Pfizer Investigational Site
Leipzig, , Germany
Pfizer Investigational Site
Mannheim, , Germany
Pfizer Investigational Site
Minden, , Germany
Pfizer Investigational Site
München, , Germany
Pfizer Investigational Site
München, , Germany
Pfizer Investigational Site
München, , Germany
Pfizer Investigational Site
Münster, , Germany
Pfizer Investigational Site
Regensburg, , Germany
Pfizer Investigational Site
Athens, Melissia, Greece
Pfizer Investigational Site
Athens, , Greece
Pfizer Investigational Site
Athens, , Greece
Pfizer Investigational Site
Thessaloniki, , Greece
Pfizer Investigational Site
Thessaloniki, , Greece
Pfizer Investigational Site
Haifa, , Israel
Pfizer Investigational Site
Holon, , Israel
Pfizer Investigational Site
Petah Tikva, , Israel
Pfizer Investigational Site
Tel Aviv, , Israel
Pfizer Investigational Site
Via Brunamonti 15, Perugia, Italy
Pfizer Investigational Site
Bari, , Italy
Pfizer Investigational Site
Bergamo, , Italy
Pfizer Investigational Site
Genova, , Italy
Pfizer Investigational Site
Milan, , Italy
Pfizer Investigational Site
Monza, , Italy
Pfizer Investigational Site
Monterrey, Nuevo León, Mexico
Pfizer Investigational Site
Rotterdam, Gelderland, Netherlands
Pfizer Investigational Site
Almelo, , Netherlands
Pfizer Investigational Site
Delft, , Netherlands
Pfizer Investigational Site
Goes, , Netherlands
Pfizer Investigational Site
RB Groningen, , Netherlands
Pfizer Investigational Site
Tilburg, , Netherlands
Pfizer Investigational Site
Takapuna, Auckland, New Zealand
Pfizer Investigational Site
Auckland, , New Zealand
Pfizer Investigational Site
Christchurch, , New Zealand
Pfizer Investigational Site
Bialystok, , Poland
Pfizer Investigational Site
Krakow, , Poland
Pfizer Investigational Site
Lublin, , Poland
Pfizer Investigational Site
Poznan, , Poland
Pfizer Investigational Site
Sosnowiec, , Poland
Pfizer Investigational Site
Warsaw, , Poland
Pfizer Investigational Site
Warsaw, , Poland
Pfizer Investigational Site
Wroclaw, , Poland
Pfizer Investigational Site
Coimbra Codex, , Portugal
Pfizer Investigational Site
Lisbon, , Portugal
Pfizer Investigational Site
Porto, , Portugal
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Bloemfontein, , South Africa
Pfizer Investigational Site
Cape Town, , South Africa
Pfizer Investigational Site
Parow, , South Africa
Pfizer Investigational Site
Alicante, Alicante, Spain
Pfizer Investigational Site
Barcelona, Barcelona, Spain
Pfizer Investigational Site
Barcelona, Barcelona, Spain
Pfizer Investigational Site
L'Hospitalet (bcn), Barcelona, Spain
Pfizer Investigational Site
Burgos, Burgos, Spain
Pfizer Investigational Site
Girona, Girona, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Málaga, Malaga, Spain
Pfizer Investigational Site
Seville, Sevilla, Spain
Pfizer Investigational Site
Seville, Sevilla, Spain
Pfizer Investigational Site
Seville, Sevilla, Spain
Pfizer Investigational Site
Valencia, Valencia, Spain
Pfizer Investigational Site
Zaragoza, Zaragoza, Spain
Pfizer Investigational Site
Palma de Mallorca, , Spain
Pfizer Investigational Site
Danderyd, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Umeå, , Sweden
Pfizer Investigational Site
Uppsala, , Sweden
Pfizer Investigational Site
Västervik, , Sweden
Pfizer Investigational Site
Aarau, , Switzerland
Pfizer Investigational Site
Basel, , Switzerland
Pfizer Investigational Site
Bern, , Switzerland
Pfizer Investigational Site
Lausanne, , Switzerland
Pfizer Investigational Site
Zurich, , Switzerland
Pfizer Investigational Site
Dundee, Scotland, United Kingdom
Pfizer Investigational Site
Newport, South Wales, United Kingdom
Pfizer Investigational Site
Aberdeen, , United Kingdom
Pfizer Investigational Site
Cardiff, , United Kingdom
Pfizer Investigational Site
Glasgow, , United Kingdom
Pfizer Investigational Site
Liverpool, , United Kingdom
Pfizer Investigational Site
Nottingham, , United Kingdom
Pfizer Investigational Site
Woolwich, , United Kingdom
Pfizer Investigational Site
Caracas, , Venezuela
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 Aug 10;355(6):549-59. doi: 10.1056/NEJMoa061894.
Chemello K, Gallo A, Guedon AF, Techer R, Croyal M, Swietek MJ, Meilhac O, Amarenco P, Lambert G. Lipoprotein(a): A Residual Cardiovascular Risk Factor in Statin-Treated Stroke Survivors: Insights From the SPARCL Trial. JACC Adv. 2023 Aug 22;2(7):100557. doi: 10.1016/j.jacadv.2023.100557. eCollection 2023 Sep.
Szarek M, Amarenco P, Callahan A, DeMicco D, Fayyad R, Goldstein LB, Laskey R, Sillesen H, Welch KM; SPARCL Committees and Investigators. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial. J Am Coll Cardiol. 2020 May 5;75(17):2110-2118. doi: 10.1016/j.jacc.2020.03.015. Epub 2020 Mar 16.
Vogt L, Bangalore S, Fayyad R, Melamed S, Hovingh GK, DeMicco DA, Waters DD. Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials. J Am Heart Assoc. 2019 May 7;8(9):e010827. doi: 10.1161/JAHA.118.010827.
Ganz P, Amarenco P, Goldstein LB, Sillesen H, Bao W, Preston GM, Welch KMA; SPARCL Steering Committee. Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Stroke. 2017 Dec;48(12):3223-3231. doi: 10.1161/STROKEAHA.117.017965. Epub 2017 Nov 7.
Byun YS, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S; SPARCL Trial Investigators. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack. J Am Coll Cardiol. 2017 Jan 17;69(2):147-158. doi: 10.1016/j.jacc.2016.10.057.
Amarenco P, Callahan A 3rd, Campese VM, Goldstein LB, Hennerici MG, Messig M, Sillesen H, Welch KM, Wilson DJ, Zivin JA. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial. Stroke. 2014 Oct;45(10):2974-82. doi: 10.1161/STROKEAHA.114.005832. Epub 2014 Aug 21.
Ovbiagele B, Goldstein LB, Amarenco P, Messig M, Sillesen H, Callahan A 3rd, Hennerici MG, Zivin J, Welch KM; SPARCL Investigators. Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial. J Stroke Cerebrovasc Dis. 2014 Apr;23(4):778-84. doi: 10.1016/j.jstrokecerebrovasdis.2013.12.001. Epub 2014 Feb 24.
Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP, Altafullah I, Ledbetter LY, MacLeod MJ, Scott R, Hennerici M, Zivin JA, Welch KM; SPARCL Investigators. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol. 2011 Oct;68(10):1245-51. doi: 10.1001/archneurol.2011.146. Epub 2011 Jun 13.
Schwartz GG, Chaitman BR, Goldberger JJ, Messig M. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Am Heart J. 2011 May;161(5):993-9. doi: 10.1016/j.ahj.2011.02.002.
Amarenco P, Goldstein LB, Sillesen H, Benavente O, Zweifler RM, Callahan A 3rd, Hennerici MG, Zivin JA, Welch KM; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2010 Mar;41(3):426-30. doi: 10.1161/STROKEAHA.109.564781. Epub 2010 Jan 28.
Amarenco P, Goldstein LB, Callahan A 3rd, Sillesen H, Hennerici MG, O'Neill BJ, Rudolph AE, Simunovic L, Zivin JA, Welch KM; SPARCL Investigators. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis. 2009 Jun;204(2):515-20. doi: 10.1016/j.atherosclerosis.2008.09.008. Epub 2008 Sep 18.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A2581138
Identifier Type: -
Identifier Source: secondary_id
0981-342
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.